| Oosterkamp, Rianne |
| Active, not recruiting | 2 | 304 | Europe | Carbo/cyclo, Carboplatin, Cyclophosphamide, Carbo/cyclo + atezolizumab, Atezolizumab, Paclitaxel, Paclitaxel + Atezolizumab | The Netherlands Cancer Institute, Borstkanker Onderzoek Groep, Roche Pharma AG | Breast Cancer | 12/24 | 12/30 | | |
| Oving, I M |
| Active, not recruiting | 2 | 304 | Europe | Carbo/cyclo, Carboplatin, Cyclophosphamide, Carbo/cyclo + atezolizumab, Atezolizumab, Paclitaxel, Paclitaxel + Atezolizumab | The Netherlands Cancer Institute, Borstkanker Onderzoek Groep, Roche Pharma AG | Breast Cancer | 12/24 | 12/30 | | |
| Holzik, Martijn Lutke |
A1Check, NCT05810207: the External Validation of a Machine Learning Model Predicting Colorectal Anastomotic Leakage |
|
|
| Recruiting | N/A | 1000 | Europe | Colorectal resection | Freek Daams, SAS Institute | Anastomotic Leak, Anastomotic Leak Large Intestine, Anastomotic Complication, Anastomotic Leak Rectum | 07/24 | 12/24 | | |
| Kok, Marleen |
TONIC-2, NCT04159818: Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) Patients |
|
|
| Recruiting | 2 | 52 | Europe | Nivolumab, Cisplatin, Low dose doxorubicin | The Netherlands Cancer Institute, Bristol-Myers Squibb | Metastatic Breast Cancer | 12/22 | 12/26 | | |
| Completed | 2 | 12 | Europe | Monalizumab, Trastuzumab | The Netherlands Cancer Institute, AstraZeneca | Breast Cancer | 01/23 | 03/24 | | |
| Active, not recruiting | 2 | 84 | Europe | Nivolumab, Radiation therapy, Low dose doxorubicin, Cyclophosphamide, Cisplatin | The Netherlands Cancer Institute, Bristol-Myers Squibb | Breast Cancer | 12/23 | 08/25 | | |
TONIC-3, NCT06342037: NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: Trial |
|
|
| Recruiting | 2 | 60 | Europe | Tiragolumab, Atezolizumab, Tecentriq, Ipilimumab, Yervoy | The Netherlands Cancer Institute, Hoffmann-La Roche | Metastatic Breast Cancer | 04/26 | 04/30 | | |
| Active, not recruiting | 2 | 304 | Europe | Carbo/cyclo, Carboplatin, Cyclophosphamide, Carbo/cyclo + atezolizumab, Atezolizumab, Paclitaxel, Paclitaxel + Atezolizumab | The Netherlands Cancer Institute, Borstkanker Onderzoek Groep, Roche Pharma AG | Breast Cancer | 12/24 | 12/30 | | |
| Recruiting | 2 | 72 | Europe | Trastuzumab deruxtecan | The Netherlands Cancer Institute, Daiichi Sankyo, AstraZeneca | HER2-positive Breast Cancer | 10/27 | 10/34 | | |
OPTImaL, NCT06476119: Optimisation of Treatment for Patients With Low Stage Triple-negative Breast Cancer With High Stromal Tumor-infiltrating Lymphocytes |
|
|
| Not yet recruiting | N/A | 490 | Europe | Adjuvant chemotherapy, according to local/ national guidelines, No adjuvant chemotherapy | The Netherlands Cancer Institute, Maarten van de Weijden Foundation, AVL Foundation | Breast Cancer Stage I, Triple Negative Breast Cancer (TNBC) | 09/32 | 09/34 | | |
NCT06273800: Chemosensitivity During Phases of the Menstrual Cycle in Breast Cancer Patients |
|
|
| Not yet recruiting | N/A | 100 | Europe | Blood sample | The Netherlands Cancer Institute | Breast Cancer | 07/35 | 07/36 | | |
| Staal, Jeske |
NVALT28, NCT04597671: Durvalumab and Low-dose PCI vs Durvalumab and Observation in Radically Treated Patients With Stage III NSCLC |
|
|
| Active, not recruiting | 3 | 170 | Europe | Durvalumab, Imfinzi, low-dose PCI, Prophylactic Cranial Irradiation (PCI) | Association NVALT Studies | Carcinoma, Non-Small-Cell Lung | 12/28 | 12/32 | | |
ELDAPT, NCT02284308: Elderly With Locally Advanced Lung Cancer: Deciding Through Geriatric Assessment on the Optimal Treatment Strategy |
|
|
| Active, not recruiting | N/A | 180 | Europe | Blood withdrawal | Maastricht Radiation Oncology, Dutch Society of Physicians for Pulmonology and Tuberculosis, Erasmus Medical Center, VieCuri Medical Centre, AstraZeneca, Dutch Cancer Society | NSCLC | 01/25 | 12/29 | | |
